Significant Long‐Term Prevention of High Sensitization After Kidney Allograft Failure by Maintaining Calcineurin Inhibitor‐Based Immunosuppression
Fuente:
Wiley Open Access
Salvato in:
| Autori principali: | , , , , , , , , , , |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2024
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1867013683963494400 |
|---|---|
| author | Anna Allesina Antonio Lavacca Fabrizio Fop Roberta Giraudi Gloria Giovinazzo Silvia Deaglio Cristiana Caorsi Caterina Dolla Ester Gallo Alberto Mella Luigi Biancone |
| author_facet | Anna Allesina Antonio Lavacca Fabrizio Fop Roberta Giraudi Gloria Giovinazzo Silvia Deaglio Cristiana Caorsi Caterina Dolla Ester Gallo Alberto Mella Luigi Biancone Anna Allesina Antonio Lavacca Fabrizio Fop Roberta Giraudi Gloria Giovinazzo Silvia Deaglio Cristiana Caorsi Caterina Dolla Ester Gallo Alberto Mella Luigi Biancone |
| collection | Wiley Open Access |
| contents | Significant Long‐Term Prevention of High Sensitization After Kidney Allograft Failure by Maintaining Calcineurin Inhibitor‐Based Immunosuppression Anna Allesina Antonio Lavacca Fabrizio Fop Roberta Giraudi Gloria Giovinazzo Silvia Deaglio Cristiana Caorsi Caterina Dolla Ester Gallo Alberto Mella Luigi Biancone Clinical Transplantation ABSTRACTIntroductionBroad national or international programs contribute to mitigating the expected longer waiting list (WL) time for sensitized patients but with minor benefits for highly sensitized subjects. Therefore, strategies to prevent high sensitization are urgently required. In this study, we investigated the risk of developing highly sensitized patients with different immunosuppressive (IS) handling after kidney allograft failure (KAF).MethodsData from 185 patients with KAF, retransplanted/relisted from 2010 to 2020 in two regions of Italy that share the same regional WL, were analyzed. Patients were categorized according to IS management at 12 months after KAF as follows: patients maintaining IS with calcineurin inhibitors (CNI) (late withdrawal group [LWG], n = 58) and those who withdrew all IS therapy or were on steroids only (early withdrawal group [EWG], n = 127).ResultsPatients in the LWG showed lower panel reactive antibodies (PRA) at 12 (29.0% vs. 85.5%, p < 0.001) and 24 months (61.0% vs. 91.0%, p = 0.001), reduced risk of high sensitization (PRA ≥90%) at 12 (9.4% vs. 40.7%, p < 0.001, OR = 0.15) and 24 months (25.6% vs. 57.3%, p = 0.001, OR = 0.26) and almost no very high sensitization (PRA ≥ 98%) at 12 months (1.9% vs. 18.6%, p = 0.003, OR = 0.08) after KAF. In the LWG subgroup analysis, patients who maintained IS for up to 24 months after KAF did not show very high sensitization. The LWG showed shorter active WL times (406 vs. 813 days, p = 0.001) without an increased risk of complications.ConclusionsCNI maintenance for at least 12 months after KAF could be a useful approach to prevent high sensitization and reduce WL times in patients who are offered retransplantation, without a higher burden of complications. 10.1111/ctr.15394 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1111/ctr.15394 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_ctr_15394 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Significant Long‐Term Prevention of High Sensitization After Kidney Allograft Failure by Maintaining Calcineurin Inhibitor‐Based Immunosuppression Anna Allesina Antonio Lavacca Fabrizio Fop Roberta Giraudi Gloria Giovinazzo Silvia Deaglio Cristiana Caorsi Caterina Dolla Ester Gallo Alberto Mella Luigi Biancone Clinical Transplantation Significant Long‐Term Prevention of High Sensitization After Kidney Allograft Failure by Maintaining Calcineurin Inhibitor‐Based Immunosuppression Anna Allesina Antonio Lavacca Fabrizio Fop Roberta Giraudi Gloria Giovinazzo Silvia Deaglio Cristiana Caorsi Caterina Dolla Ester Gallo Alberto Mella Luigi Biancone Clinical Transplantation ABSTRACTIntroductionBroad national or international programs contribute to mitigating the expected longer waiting list (WL) time for sensitized patients but with minor benefits for highly sensitized subjects. Therefore, strategies to prevent high sensitization are urgently required. In this study, we investigated the risk of developing highly sensitized patients with different immunosuppressive (IS) handling after kidney allograft failure (KAF).MethodsData from 185 patients with KAF, retransplanted/relisted from 2010 to 2020 in two regions of Italy that share the same regional WL, were analyzed. Patients were categorized according to IS management at 12 months after KAF as follows: patients maintaining IS with calcineurin inhibitors (CNI) (late withdrawal group [LWG], n = 58) and those who withdrew all IS therapy or were on steroids only (early withdrawal group [EWG], n = 127).ResultsPatients in the LWG showed lower panel reactive antibodies (PRA) at 12 (29.0% vs. 85.5%, p < 0.001) and 24 months (61.0% vs. 91.0%, p = 0.001), reduced risk of high sensitization (PRA ≥90%) at 12 (9.4% vs. 40.7%, p < 0.001, OR = 0.15) and 24 months (25.6% vs. 57.3%, p = 0.001, OR = 0.26) and almost no very high sensitization (PRA ≥ 98%) at 12 months (1.9% vs. 18.6%, p = 0.003, OR = 0.08) after KAF. In the LWG subgroup analysis, patients who maintained IS for up to 24 months after KAF did not show very high sensitization. The LWG showed shorter active WL times (406 vs. 813 days, p = 0.001) without an increased risk of complications.ConclusionsCNI maintenance for at least 12 months after KAF could be a useful approach to prevent high sensitization and reduce WL times in patients who are offered retransplantation, without a higher burden of complications. 10.1111/ctr.15394 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Significant Long‐Term Prevention of High Sensitization After Kidney Allograft Failure by Maintaining Calcineurin Inhibitor‐Based Immunosuppression |
| topic | Clinical Transplantation |
| url | https://onlinelibrary.wiley.com/doi/10.1111/ctr.15394 |